Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 2/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL4295359 | 0.80 | SNCA (0.40) | SNCAHIF1ASLC6A2SLC6A4ALDH1A1 | |
| Bromide SCHEMBL4287071 | 0.80 | HIF1A (0.46) | SNCAHIF1AALDH1A1CYP1A2CYP2D6 | |
| Bromide SCHEMBL4150321 | 0.77 | SNCA (0.40) | SNCAHIF1AALDH1A1CYP1A2CYP2D6 | |
| Bromide SCHEMBL1681703 | 0.76 | MMP1 (0.38) | CYP1A2TSHR | |
| Bromide SCHEMBL2446627 | 0.71 | HIF1A (0.55) | SNCAHIF1ASLC6A2SLC6A4ALDH1A1 | |
| Bromide SCHEMBL14723185 | 0.71 | SNCA (0.61) | SNCAHIF1AALDH1A1CYP1A2CYP2D6 | |
| Bromide SCHEMBL11060728 | 0.71 | HIF1A (0.44) | SNCAHIF1AALDH1A1CYP1A2CYP2D6 | |
| Bromide SCHEMBL17141383 | 0.70 | SNCA (0.47) | SNCAHIF1ASLC6A2SLC6A4CYP1A2 | |
| Bromide SCHEMBL2552144 | 0.70 | BACE1 (0.39) | SNCAHIF1AALDH1A1CYP1A2CYP2D6 | |
| Bromide SCHEMBL4293626 | 0.70 | SNCA (0.37) | SNCAHIF1ASLC6A4ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253687-A1 | Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253687-A1 | Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands | NR3C2, NR3C1, MC2R | SNCA 4830/4885HIF1A 3046/4885SLC6A2 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.